Prime Medicine Inc (NASDAQ:PRME) has a beta value of 1.85 and has seen 0.56 million shares traded in the recent trading session. The company, currently valued at $426.34M, closed the recent trade at $3.25 per share which meant it gained $0.41 on the day or 14.45% during that session. The PRME stock price is -200.62% off its 52-week high price of $9.77 and 30.77% above the 52-week low of $2.25. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.16 million shares traded. The 3-month trading volume is 1.09 million shares.
The consensus among analysts is that Prime Medicine Inc (PRME) is Buy stock at the moment, with a recommendation rating of 1.20. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 5 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.31.
Prime Medicine Inc (NASDAQ:PRME) trade information
Sporting 14.45% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the PRME stock price touched $3.25 or saw a fall of -1.88%. Year-to-date, Prime Medicine Inc shares have moved 11.32%, while the 5-day performance has seen it change 34.32%. Over the past 30 days, the shares of Prime Medicine Inc (NASDAQ:PRME) have changed 13.26%. Short interest in the company has seen 17.3 million shares shorted with days to cover at 20.76.
Wall Street analysts have a consensus price target for the stock at $17, which means that the shares’ value could jump 80.88% from the levels at last check today. The projected low price target is $12.0 while the price target rests at a high of $23.0. In that case, then, we find that the latest price level in today’s session is -607.69% off the targeted high while a plunge would see the stock gain -269.23% from the levels at last check today.
Prime Medicine Inc (PRME) estimates and forecasts
The company’s shares have lost -25.96% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%.
9 analysts offering their estimates for the company have set an average revenue estimate of 5.81M for the current quarter. 5 have an estimated revenue figure of 4.55M for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -193.88% over the past 5 years. Earnings growth for 2025 is a modest 26.60% while over the next 5 years, the company’s earnings are expected to increase by 20.17%.
PRME Dividends
Prime Medicine Inc is expected to release its next earnings report in March this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Prime Medicine Inc (NASDAQ:PRME)’s Major holders
Insiders own 23.91% of the company shares, while shares held by institutions stand at 58.97% with a share float percentage of 77.49%. Investors are also buoyed by the number of investors in a company, with Prime Medicine Inc having a total of 172.0 institutions that hold shares in the company.
Also the top two Mutual Funds that are holding company’s shares are ARK ETF Tr-ARK Genomic Revolution ETF and ARK ETF Tr-ARK Innovation ETF. As of Dec 31, 2024, the former fund manager holds about 1.84% shares in the company for having 2.41 shares of worth $7.78 million while later fund manager owns 2.23 shares of worth $7.18 million as of Dec 31, 2024, which makes it owner of about 1.70% of company’s outstanding stock.
